🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Development of a Multidimensional Prediction Model for the Course and Outcome of Early-Onset Juvenile Idiopathic Arthritis (JIA)

Recruitingn/aAges 2 Years - 17 YearsAllIstituto Giannina Gaslini
NCT07882667 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective-retrospective, translational, no profit, multicentric, observational study. A cohort of at least 100 early-onset JIA patients attending the Unit of Rheumatology and Autoinflammatory Diseases, Department of Pediatric Sciences, IRCCS Istituto Giannina Gaslini or selected Italian pediatric rheumatology centers, will be enrolled and evaluated at onset and at 5 time points of follow up to 24 months (month 3, month 6, month 12, month 18 and month 24) to monitor the course of the disease. A cohort of 30 patients with Iridocyclitis not correlated to JIA will be recruited in parallel at the time of disease diagnosis as a group of control for comparison.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * For patients with JIA * A diagnosis of JIA according to the ILAR criteria by the treating pediatric rheumatologist * Classification in one of the following ILAR JIA categories: oJIA, RF-pJIA, PsA, or undifferentiated arthritis * Age \< 6 years at onset * Onset of JIA symptoms no more than 6 months before enrolment * Duly executed, written, informed consent/assent obtained from the parents/patient. For control subjects * A diagnosis of Iridocyclitis not correlated to JIA by the treating pediatric ophtalmologist * Age ≤ 17 years at diagnosis * Duly executed, written, informed consent/assent obtained from the parents/patient. Exclusion Criteria: * For patients with JIA * Classification in one of the following ILAR JIA categories: systemic arthritis, RF-positive polyarthritis, enthesitis-related arthritis * Previous treatment with any synthetic or biologic DMARD before biologic sample collection. For control subjects ● Previous treatment with any synthetic or biologic DMARD before biologic sample collection.
💊

What it tests

  • Not listed
📍

Where

2 sites
IRCCS Istituto Giannina Gaslini
Genova, Italy
Ospedale Vito Fazzi
Lecce, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy